List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8768163/publications.pdf Version: 2024-02-01



ANNE RADION

#	Article	IF	CITATIONS
1	Towards Personalising the Use of Biologics in Rheumatoid Arthritis: A Discrete Choice Experiment. Patient, 2022, 15, 109-119.	1.1	1
2	Pre-defined gene co-expression modules in rheumatoid arthritis transition towards molecular health following anti-TNF therapy. Rheumatology, 2022, 61, 4935-4944.	0.9	3
3	HLA-DRB1 haplotypes predict cardiovascular mortality in inflammatory polyarthritis independent of CRP and anti-CCP status. Arthritis Research and Therapy, 2022, 24, 90.	1.6	3
4	P200 Combining protein quantitative trait and genetic risk score analysis to identify biomarkers of treatment response to TNFi in patients with rheumatoid arthritis. Rheumatology, 2022, 61, .	0.9	0
5	OA24â€fPredicting drug immunogenicity to tumour necrosis factor inhibitors in patients with rheumatoid arthritis. Rheumatology, 2022, 61, .	0.9	0
6	P190 Unsupervised automated clustering of mass cytometry data identifies unique CD4+ T cell subsets in rheumatoid arthritis. Rheumatology, 2022, 61, .	0.9	0
7	OA15â€fDrivers of change in four and two component disease activity scores after etanercept treatment, in a multi-centre cohort of patients with established rheumatoid arthritis. Rheumatology, 2022, 61, .	0.9	0
8	P189 A longitudinal study of psychological predictors of response to adalimumab in patients with rheumatoid arthritis. Rheumatology, 2022, 61, .	0.9	1
9	Comparative Genetic Analysis of Psoriatic Arthritis and Psoriasis for the Discovery of Genetic Risk Factors and Risk Prediction Modeling. Arthritis and Rheumatology, 2022, 74, 1535-1543.	2.9	15
10	OA28 Exploring the potential of polygenic risk scores for predicting coronary artery disease in patients with rheumatoid arthritis. Rheumatology, 2022, 61, .	0.9	0
11	OA16 Therapeutic certolizumab pegol drug levels to achieve good EULAR response in patients with rheumatoid arthritis: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS) cohort. Rheumatology, 2022, 61, .	0.9	0
12	Translating research into clinical practice: quality improvement to halve non-adherence to methotrexate. Rheumatology, 2021, 60, 125-131.	0.9	6
13	Changes in the illness perceptions of patients with rheumatoid arthritis over the first year of methotrexate therapy. Rheumatology, 2021, 60, 2355-2365.	0.9	11
14	Machine learning in precision medicine: lessons to learn. Nature Reviews Rheumatology, 2021, 17, 5-6.	3.5	18
15	Do people with rheumatoid arthritis maintain their physical activity level at treatment onset over the first year of methotrexate therapy?. Rheumatology, 2021, 60, 4633-4642.	0.9	5
16	Prediction of response of methotrexate in patients with rheumatoid arthritis using serum lipidomics. Scientific Reports, 2021, 11, 7266.	1.6	21
17	Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment. Arthritis Research and Therapy, 2021, 23, 80.	1.6	11
18	O08 Developing a DNA methylation signature for predicting rheumatoid arthritis using a machine learning pipeline. Rheumatology, 2021, 60, .	0.9	0

#	Article	IF	CITATIONS
19	Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes. Annals of the Rheumatic Diseases, 2021, 80, 1040-1047.	0.5	24
20	Cell-specific epigenetic drivers of pathogenesis in rheumatoid arthritis. Epigenomics, 2021, 13, 549-560.	1.0	4
21	Robust optimization of SWATH-MS workflow for human blood serum proteome analysis using a quality by design approach. Clinical Proteomics, 2021, 18, 20.	1.1	2
22	Application of information theoretic feature selection and machine learning methods for the development of genetic risk prediction models. Scientific Reports, 2021, 11, 23335.	1.6	10
23	The predictors of and reasons for non-adherence in an observational cohort of patients with rheumatoid arthritis commencing methotrexate. Rheumatology, 2020, 59, 213-223.	0.9	22
24	Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to diseaseâ€associated psychological morbidity. British Journal of Dermatology, 2020, 182, 130-137.	1.4	52
25	Adding value to real-world data: the role of biomarkers. Rheumatology, 2020, 59, 31-38.	0.9	11
26	Differential DNA methylation correlates with response to methotrexate in rheumatoid arthritis. Rheumatology, 2020, 59, 1364-1371.	0.9	43
27	Long-term outcomes of patients who rate symptoms of rheumatoid arthritis as †satisfactory'. Rheumatology, 2020, 59, 1853-1861.	0.9	8
28	Proteomic analysis to define predictors of treatment response to adalimumab or methotrexate in rheumatoid arthritis patients. Pharmacogenomics Journal, 2020, 20, 516-523.	0.9	6
29	The use of missing values in proteomic data-independent acquisition mass spectrometry to enable disease activity discrimination. Bioinformatics, 2020, 36, 2217-2223.	1.8	29
30	Therapeutic monitoring of TNF inhibitors for rheumatoid arthritis: evidence required following NICE's recommendations. Rheumatology Advances in Practice, 2020, 4, rkaa023.	0.3	0
31	O11 Lymphocyte DNA methylation mediates genetic risk at RA risk loci that are shared with other immune mediated diseases. Rheumatology, 2020, 59, .	0.9	0
32	Characterisation of CD4+ T-cell subtypes using single cell RNA sequencing and the impact of cell number and sequencing depth. Scientific Reports, 2020, 10, 19825.	1.6	17
33	Genetic feature engineering enables characterisation of shared risk factors in immune-mediated diseases. Genome Medicine, 2020, 12, 106.	3.6	12
34	Investigation of genetically regulated gene expression and response to treatment in rheumatoid arthritis highlights an association between <i>IL18RAP</i> expression and treatment response. Annals of the Rheumatic Diseases, 2020, 79, 1446-1452.	0.5	13
35	Using functional genomics to advance the understanding of psoriatic arthritis. Rheumatology, 2020, 59, 3137-3146.	0.9	8
36	Predicting treatment response to IL6R blockers in rheumatoid arthritis. Rheumatology, 2020, 59, 3603-3610.	0.9	15

#	Article	IF	CITATIONS
37	Latent Class Trajectory Modeling of 2â€Component Disease Activity Score in 28 Joints Identifies Multiple Rheumatoid Arthritis Phenotypes of Response to Biologic Diseaseâ€Modifying Antirheumatic Drugs. Arthritis and Rheumatology, 2020, 72, 1632-1642.	2.9	9
38	Personalized medicine in rheumatic diseases: how close are we to being able to use genetic biomarkers to predict response to TNF inhibitors?. Expert Review of Clinical Immunology, 2020, 16, 389-396.	1.3	8
39	Predictors of presenteeism, absenteeism and job loss in patients commencing methotrexate or biologic therapy for rheumatoid arthritis. Rheumatology, 2020, 59, 2908-2919.	0.9	17
40	A restricted spectrum of missense KMT2D variants cause a multiple malformations disorder distinct fromKabuki syndrome. Genetics in Medicine, 2020, 22, 867-877.	1.1	41
41	Lymphocyte DNA methylation mediates genetic risk at shared immune-mediated disease loci. Journal of Allergy and Clinical Immunology, 2020, 145, 1438-1451.	1.5	20
42	Association of Pharmacological Biomarkers with Treatment Response and Longterm Disability in Patients with Psoriatic Arthritis: Results from OUTPASS. Journal of Rheumatology, 2020, 47, 1204-1208.	1.0	10
43	Pharmacogenetics of TNF inhibitorÂresponse in rheumatoid arthritis utilizing the two-component disease activity score. Pharmacogenomics, 2020, 21, 1151-1156.	0.6	3
44	THU0022â€DIFFERENTIAL DNA METHYLATION AS A PREDICTOR OF TOCILIZUMAB RESPONSE IN RHEUMATOID ARTHRITIS PATIENTS. Annals of the Rheumatic Diseases, 2020, 79, 224.1-224.	0.5	0
45	THU0005â€VARIABILITY OF DNA METHYLATION IS A DRIVER OF LYMPHOCYTE DYSREGULATION IN EARLY RHEUMATOID ARTHRITIS Annals of the Rheumatic Diseases, 2020, 79, 215.2-215.	0.5	0
46	058 Investigating the pharmacogenetics of anti-TNF response in patients with rheumatoid arthritis utilising the re-weighted disease activity score: results from the biologics in rheumatoid arthritis genetics and genomics study syndicate. Rheumatology, 2019, 58, .	0.9	0
47	Distinct HLA Associations with Rheumatoid Arthritis Subsets Defined by Serological Subphenotype. American Journal of Human Genetics, 2019, 105, 616-624.	2.6	27
48	Translational genomics and precision medicine: Moving from the lab to the clinic. Science, 2019, 365, 1409-1413.	6.0	133
49	Using the Immunophenotype to Predict Response to Biologic Drugs in Rheumatoid Arthritis. Journal of Personalized Medicine, 2019, 9, 46.	1.1	13
50	Development and validation of a methotrexate adherence assay. Annals of the Rheumatic Diseases, 2019, 78, 1192-1197.	0.5	13
51	I051â $\in$ fWhat do we mean by treatment response and can we predict it?. Rheumatology, 2019, 58, .	0.9	0
52	Chromatin interactions reveal novel gene targets for drug repositioning in rheumatic diseases. Annals of the Rheumatic Diseases, 2019, 78, 1127-1134.	0.5	23
53	055 Can interleukin IL-17A levels predict response to biologic treatment in patients with rheumatoid arthritis?. Rheumatology, 2019, 58, .	0.9	0
54	Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for <i>CD40</i> and CD39. Annals of the Rheumatic Diseases, 2019, 78, 1055-1061.	0.5	25

#	Article	IF	CITATIONS
55	Validity of a two-component imaging-derived disease activity score for improved assessment of synovitis in early rheumatoid arthritis. Rheumatology, 2019, 58, 1400-1409.	0.9	39
56	Expression of STAT3-regulated genes in circulating CD4+ T cells discriminates rheumatoid arthritis independently of clinical parameters in early arthritis. Rheumatology, 2019, 58, 1250-1258.	0.9	14
57	SATO062â€STRATIFIED MEDICINE FOR RHEUMATOID ARTHRITIS: PREDICTING RESPONSE TO BIOLOGIC THERAP USING IMMUNE CELL SIGNATURES. , 2019, , .	Y	0
58	P106/O25â€DNA methylation in lymphocyte subsets as a mediator of genetic risk in early rheumatoid arthritis. , 2019, , .		0
59	FRI0004â€CHROMATIN INTERACTIONS IN NOVEL CELL TYPES REVEAL PARK7 AND ERRFI1 AS PUTATIVE CAUSAL GENES IN THE SUSCEPTIBILITY TO PSORIATIC ARTHRITIS. , 2019, , .		0
60	Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification?. Current Opinion in Rheumatology, 2019, 31, 285-292.	2.0	39
61	Profiling of Gene Expression Biomarkers as a Classifier of Methotrexate Nonresponse in Patients With Rheumatoid Arthritis. Arthritis and Rheumatology, 2019, 71, 678-684.	2.9	50
62	Prediction of response to methotrexate in rheumatoid arthritis. Expert Review of Clinical Immunology, 2018, 14, 419-429.	1.3	23
63	Rheumatoid arthritis. Nature Reviews Disease Primers, 2018, 4, 18001.	18.1	1,441
64	Genotypic variability-based genome-wide association study identifies non-additive loci HLA-C and IL12B for psoriasis. Journal of Human Genetics, 2018, 63, 289-296.	1.1	9
65	Genetics of immune-mediated inflammatory diseases. Clinical and Experimental Immunology, 2018, 193, 3-12.	1.1	66
66	O12 Validity of a2-component imaging-derived disease activity score (2C-DAS28) for improved assessment of synovitis in early rheumatoid arthritis. Rheumatology, 2018, 57, .	0.9	0
67	248 Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis. Rheumatology, 2018, 57, .	0.9	0
68	CD4+ and B Lymphocyte Expression Quantitative Traits at Rheumatoid Arthritis Risk Loci in Patients With Untreated Early Arthritis. Arthritis and Rheumatology, 2018, 70, 361-370.	2.9	37
69	227 Predictors of presenteeism and absenteeism in patients commencing treatment with methotrexate monotherapy or biologic therapy for rheumatoid arthritis. Rheumatology, 2018, 57, .	0.9	0
70	e11 Patterns of the patient acceptable symptom state over 12 months following the initiation of methotrexate therapy in patients with rheumatoid arthritis, and the association between these patterns and disability and disease activity. Rheumatology, 2018, 57, .	0.9	0
71	P124â€Altered CD4+ T cell DNA methylation in early rheumatoid arthritis. , 2018, , .		0
72	089 The association between poor prognostic factors at methotrexate initiation and disease activity and disability over one year: results from the Rheumatoid Arthritis Medication Study. Rheumatology, 2018, 57, .	0.9	0

#	Article	IF	CITATIONS
73	e12 Clinical phenotypes of patients with rheumatoid arthritis who identify as in a patient acceptable symptom state at methotrexate initiation and a comparison of the outcome of these phenotypes over 12 months. Rheumatology, 2018, 57, .	0.9	0
74	Prediction of treatment response in rheumatoid arthritis patients using genomeâ€wide SNP data. Genetic Epidemiology, 2018, 42, 754-771.	0.6	15
75	Increased DNA methylation variability in rheumatoid arthritis-discordant monozygotic twins. Genome Medicine, 2018, 10, 64.	3.6	71
76	Assessing the Role of DNA Methylation-Derived Neutrophil-to-Lymphocyte Ratio in Rheumatoid Arthritis. Journal of Immunology Research, 2018, 2018, 1-10.	0.9	13
77	Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis. Pharmacogenomics Journal, 2018, 18, 657-664.	0.9	41
78	Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients. Pharmacogenomics Journal, 2018, 18, 528-538.	0.9	42
79	Psoriasis and Psoriatic Arthritis. , 2018, , 239-250.		0
80	Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS). Arthritis Research and Therapy, 2018, 20, 147.	1.6	73
81	The prevalence of co-morbidities and their impact on physical activity in people with inflammatory rheumatic diseases compared with the general population: results from the UK Biobank. Rheumatology, 2018, 57, 2172-2182.	0.9	30
82	THU0001â€Differential methylation as a predictor of methotrexate response in patients with rheumatoid arthritis. , 2018, , .		0
83	Optimisation of methods for bacterial skin microbiome investigation: primer selection and comparison of the 454 versus MiSeq platform. BMC Microbiology, 2017, 17, 23.	1.3	133
84	High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort. Annals of the Rheumatic Diseases, 2017, 76, 208-213.	0.5	49
85	Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA. RMD Open, 2017, 3, e000314.	1.8	29
86	HLA-A 31:01 is not associated with the development of methotrexate pneumonitis in the UK population: results from a genome-wide association study. Annals of the Rheumatic Diseases, 2017, 76, e51-e51.	0.5	11
87	A rare coding allele inIFIH1is protective for psoriatic arthritis. Annals of the Rheumatic Diseases, 2017, 76, 1321-1324.	0.5	22
88	Genetics of rheumatoid arthritis susceptibility, severity, and treatment response. Seminars in Immunopathology, 2017, 39, 395-408.	2.8	73
89	Cross-phenotype association mapping of the MHC identifies genetic variants that differentiate psoriatic arthritis from psoriasis. Annals of the Rheumatic Diseases, 2017, 76, 1774-1779.	0.5	51
90	DNA methylation as a marker of response in rheumatoid arthritis. Pharmacogenomics, 2017, 18, 1323-1332.	0.6	22

#	Article	IF	CITATIONS
91	Genotypic variability based association identifies novel non-additive loci DHCR7 and IRF4 in sero-negative rheumatoid arthritis. Scientific Reports, 2017, 7, 5261.	1.6	20
92	Precision Medicine in Rheumatoid Arthritis. Rheumatic Disease Clinics of North America, 2017, 43, 377-387.	0.8	42
93	Brief Report: The Role of Rare Proteinâ€Coding Variants in Anti–Tumor Necrosis Factor Treatment Response in Rheumatoid Arthritis. Arthritis and Rheumatology, 2017, 69, 735-741.	2.9	8
94	Investigation of the genetic overlap between rheumatoid arthritis and psoriatic arthritis in a Greek population. Scandinavian Journal of Rheumatology, 2017, 46, 180-186.	0.6	14
95	05.10â€Comparison of cd4+ and b lymphocyte expression quantitative trait associations at ra risk loci in untreated early arthritis patients. , 2017, , .		0
96	Stratified medicine in rheumatoid arthritis—the MATURA programme. Rheumatology, 2017, 56, 1247-1250.	0.9	22
97	THU0003â€CD4+ and B lymphocyte expression quantitative traits at rheumatoid arthritis risk loci in untreated early arthritis: implications for causal gene identification?. , 2017, , .		2
98	THU0001â€Differential methylation as a potential biomarker of methotrexate response in patients with rheumatoid arthritis. , 2017, , .		0
99	THU0004â€Cross phenotype association mapping of the mhc identifies genetic variants that differentiate psoriatic arthritis from psoriasis. , 2017, , .		0
100	OP0298â€Chromatin interactions reveal novel gene targets for drug repositioning in rheumatic diseases. , 2017, , .		0
101	FRI0724â€Predictors of presenteeism and absenteeism in patients commencing treatment with methotrexate monotherapy or biologic therapy for rheumatoid arthritis. , 2017, , .		0
102	Genetics of Rheumatic Diseases. , 2017, , 327-343.		0
103	The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort. Rheumatology, 2017, 56, kew387.	0.9	10
104	<i>KIF3A</i> and <i>IL-4</i> are disease-specific biomarkers for psoriatic arthritis susceptibility. Oncotarget, 2017, 8, 95401-95411.	0.8	12
105	Capture Hi-C identifies a novel causal gene, IL20RA, in the pan-autoimmune genetic susceptibility region 6q23. Genome Biology, 2016, 17, 212.	3.8	85
106	HLA–DRB1 Amino Acid Positions 11/13, 71, and 74 Are Associated With Inflammation Level, Disease Activity, and the Health Assessment Questionnaire Score in Patients With Inflammatory Polyarthritis. Arthritis and Rheumatology, 2016, 68, 2618-2628.	2.9	23
107	OP0235â€Identification of Novel Cd4+ Lymphocyte Expression Quantitative Trait Loci in Untreated Early Arthritis Patients. Annals of the Rheumatic Diseases, 2016, 75, 147.1-147.	0.5	0
108	Psychological factors predict adherence to methotrexate in rheumatoid arthritis; findings from a systematic review of rates, predictors and associations with patient-reported and clinical outcomes. RMD Open, 2016, 2, e000171.	1.8	40

#	Article	IF	CITATIONS
109	SAT0009â€Investigation of Differential Methylation as A Potential Biomarker of Methotrexate Response in Patients with Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 667.1-667.	O.5	0
110	Cryopreservation of cells does not substantially alter the DNA methylome of CD3+CD4+ T cells. Scandinavian Journal of Rheumatology, 2016, 45, 329-330.	0.6	0
111	A microcosting study of immunogenicity and tumour necrosis factor alpha inhibitor drug level tests for therapeutic drug monitoring in clinical practice. Rheumatology, 2016, 55, 2131-2137.	0.9	14
112	Differential Methylation as a Biomarker of Response to Etanercept in Patients With Rheumatoid Arthritis. Arthritis and Rheumatology, 2016, 68, 1353-1360.	2.9	59
113	Replication of Associations of Genetic Loci Outside the HLA Region With Susceptibility to Anti–Cyclic Citrullinated Peptide–Negative Rheumatoid Arthritis. Arthritis and Rheumatology, 2016, 68, 1603-1613.	2.9	33
114	Association Between Genetic Variation in <i>FOXO3</i> and Reductions in Inflammation and Disease Activity in Inflammatory Polyarthritis. Arthritis and Rheumatology, 2016, 68, 2629-2636.	2.9	32
115	Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels. Rheumatology, 2016, 55, 2050-2055.	0.9	14
116	Rheumatoid arthritis patient perceptions on the value of predictive testing for treatments: a qualitative study. BMC Musculoskeletal Disorders, 2016, 17, 460.	0.8	9
117	Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. Nature Communications, 2016, 7, 12460.	5.8	73
118	AB0727â€Increased Rates of Hypertension in Patients with Psoriatic Arthritis Compared To Psoriasis Alone: Results from The UK Biobank: Table 1 Annals of the Rheumatic Diseases, 2016, 75, 1153.1-1153.	0.5	1
119	A6.13â€Identification of novel expression quantitative trait loci in CD4+T cells of untreated early arthritis patients. Annals of the Rheumatic Diseases, 2016, 75, A52.2-A52.	0.5	0
120	AB0005â€Weighted Gene Co-Expression Network Analysis Reveals Link between Protein Kinase Signalling and Response To Methotrexate in New-Onset Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 898.2-898.	0.5	0
121	Replication of a distinct psoriatic arthritis risk variant at theIL23Rlocus. Annals of the Rheumatic Diseases, 2016, 75, 1417-1418.	0.5	9
122	Previously reported <i>PDE3A–SLCO1C1</i> genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohort. Pharmacogenomics, 2016, 17, 715-720.	0.6	9
123	Association of Toll-like receptor 4 (TLR4) with chronic plaque type psoriasis and psoriatic arthritis. Archives of Dermatological Research, 2016, 308, 201-205.	1.1	35
124	One SNP at a Time: Moving beyond GWAS in Psoriasis. Journal of Investigative Dermatology, 2016, 136, 567-573.	0.3	48
125	Identifying a novel locus for psoriatic arthritis. Rheumatology, 2016, 55, 25-32.	0.9	13
126	Loci associated with N-glycosylation of human lgG are not associated with rheumatoid arthritis: a Mendelian randomisation study. Annals of the Rheumatic Diseases, 2016, 75, 317-320.	0.5	19

#	Article	IF	CITATIONS
127	Anticarbamylated protein antibodies are associated with long-term disability and increased disease activity in patients with early inflammatory arthritis: results from the Norfolk Arthritis Register. Annals of the Rheumatic Diseases, 2016, 75, 1139-1144.	0.5	41
128	Identifying Causal Genes at the Multiple Sclerosis Associated Region 6q23 Using Capture Hi-C. PLoS ONE, 2016, 11, e0166923.	1.1	28
129	Do lean markers relate to exacerbation rate in chronic obstructive pulmonary disease? Preliminary results from AERIS study. Proceedings of the Nutrition Society, 2015, 74, .	0.4	0
130	Rheumatoid arthritis response to treatment across IgG1 allotype – anti-TNF incompatibility: a case-only study. Arthritis Research and Therapy, 2015, 17, 63.	1.6	9
131	Investigating CD11c expression as a potential genomic biomarker of response to TNF inhibitor biologics in whole blood rheumatoid arthritis samples. Arthritis Research and Therapy, 2015, 17, 359.	1.6	6
132	SAT0345â€Lifestyle, Clinical and Psychosocial Predictors of Good Response to Methotrexate Therapy in the Rheumatoid Arthritis Medication Study (RAMS). Annals of the Rheumatic Diseases, 2015, 74, 783.3-784.	0.5	1
133	O53. PTPN22 is Associated with Susceptibility to Psoriatic Arthritis but not Psoriasis: Evidence for a Further PSA-Specific Risk Locus. Rheumatology, 2015, , .	0.9	1
134	054. The Importance of IL-6-STAT3 Mediated Activation of Circulating CD4 <sup>+</sup> T Cells in the Pathogenesis of Early Seronegative Rheumatoid Arthritis: A Validation Study. Rheumatology, 2015, , .	0.9	0
135	Statistical colocalization of genetic risk variants for related autoimmune diseases in the context of common controls. Nature Genetics, 2015, 47, 839-846.	9.4	128
136	Pharmacogenetics of Treatment Response in Psoriatic Arthritis. Current Rheumatology Reports, 2015, 17, 44.	2.1	16
137	Reply. Arthritis Care and Research, 2015, 67, 452-453.	1.5	0
138	Capture Hi-C reveals novel candidate genes and complex long-range interactions with related autoimmune risk loci. Nature Communications, 2015, 6, 10069.	5.8	161
139	PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus. Annals of the Rheumatic Diseases, 2015, 74, 1882-1885.	0.5	64
140	Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Rheumatology, 2015, 54, 494-499.	0.9	90
141	The skin microbiome in psoriatic arthritis: methodology development and pilot data. Lancet, The, 2015, 385, S27.	6.3	7
142	O10. Risk and Characteristics of Drug-Induced Lupus in Patients Exposed to Tumour Necrosis Factor-α Inhibitor Therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology, 2015, , .	0.9	0
143	Association of HLA-DRB1 Haplotypes With Rheumatoid Arthritis Severity, Mortality, and Treatment Response. JAMA - Journal of the American Medical Association, 2015, 313, 1645.	3.8	119
144	O49. Personalized Genetic Medicine: Amino Acid Positions 11, 71 and 74 in HLA-DRB1 Predict Disease Severity, Mortality and Treatment Response in Rheumatoid Arthritis—Multi-Centre Prospective Cohort Studies. Rheumatology, 2015, , .	0.9	0

#	Article	IF	CITATIONS
145	A HPLC-SRM-MS based method for the detection and quantification of methotrexate in urine at doses used in clinical practice for patients with rheumatological disease: a potential measure of adherence. Analyst, The, 2015, 140, 1981-1987.	1.7	23
146	A weighted genetic risk score using all known susceptibility variants to estimate rheumatoid arthritis risk. Annals of the Rheumatic Diseases, 2015, 74, 170-176.	0.5	55
147	Association of anti-carbamylated protein antibodies with long-term disability and increased disease activity in patients with early inflammatory arthritis: results from the Norfolk Arthritis Register. Lancet, The, 2015, 385, S44.	6.3	10
148	Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis. Lancet, The, 2015, 385, S48.	6.3	18
149	Clinical Utility of Random Anti–Tumor Necrosis Factor Drug–Level Testing and Measurement of Antidrug Antibodies on the Longâ€Term Treatment Response in Rheumatoid Arthritis. Arthritis and Rheumatology, 2015, 67, 2011-2019.	2.9	90
150	Association of chemokine CXC ligand 12 gene polymorphism (rs1746048) with cardiovascular mortality in patients with rheumatoid arthritis: results from the Norfolk Arthritis Register: TableÂ1. Annals of the Rheumatic Diseases, 2015, 74, 2099-2102.	0.5	8
151	Genetic and genomic markers of anti-TNF treatment response in rheumatoid arthritis. Biomarkers in Medicine, 2015, 9, 499-512.	0.6	29
152	Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. Nature Communications, 2015, 6, 6046.	5.8	149
153	Identification of loci associated with late-onset psoriasis using dense genotyping of immune-related regions. British Journal of Dermatology, 2015, 172, 933-939.	1.4	17
154	TYK2 Protein-Coding Variants Protect against Rheumatoid Arthritis and Autoimmunity, with No Evidence of Major Pleiotropic Effects on Non-Autoimmune Complex Traits. PLoS ONE, 2015, 10, e0122271.	1.1	120
155	Integration of Sequence Data from a Consanguineous Family with Genetic Data from an Outbred Population Identifies PLB1 as a Candidate Rheumatoid Arthritis Risk Gene. PLoS ONE, 2014, 9, e87645.	1.1	34
156	SAT0095â€Control of Disease Activity is Associated with Improvement in Physical Activity in Patients with Rheumatoid Arthritis: Table 1. Annals of the Rheumatic Diseases, 2014, 73, 624.3-625.	0.5	0
157	Polymorphisms in IL-1B Distinguish between Psoriasis of Early and Late Onset. Journal of Investigative Dermatology, 2014, 134, 1459-1462.	0.3	26
158	Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Pharmacogenomics Journal, 2014, 14, 171-175.	0.9	3
159	Impact of Psychological Factors on Subjective Disease Activity Assessments in Patients With Severe Rheumatoid Arthritis. Arthritis Care and Research, 2014, 66, 861-868.	1.5	71
160	The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology, 2014, 53, 213-222.	0.9	177
161	Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. Annals of the Rheumatic Diseases, 2014, 73, 1202-1210.	0.5	166
162	Novel Rheumatoid Arthritis Susceptibility Locus at 22q12 Identified in an Extended UK Genomeâ€Wide Association Study. Arthritis and Rheumatology, 2014, 66, 24-30.	2.9	41

#	Article	IF	CITATIONS
163	Genetic and epigenetic predictors of responsiveness to treatment in RA. Nature Reviews Rheumatology, 2014, 10, 329-337.	3.5	78
164	Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature, 2014, 506, 376-381.	13.7	1,974
165	Economics of Stratified Medicine in Rheumatoid Arthritis. Current Rheumatology Reports, 2014, 16, 468.	2.1	8
166	Investigation of an interleukin-6 receptor gene polymorphism (rs2228145) as a predictor of cardiovascular mortality in inflammatory polyarthritis: results from the Norfolk Arthritis Register: TableÂ1. Annals of the Rheumatic Diseases, 2014, 73, 787-788.	0.5	8
167	Testing the role of vitamin D in response to antitumour necrosis factor α therapy in a UK cohort: a Mendelian randomisation approach. Annals of the Rheumatic Diseases, 2014, 73, 938-940.	0.5	6
168	The role of genetic polymorphisms regulating vitamin D levels in rheumatoid arthritis outcome: a Mendelian randomisation approach. Annals of the Rheumatic Diseases, 2014, 73, 1430-1433.	0.5	11
169	The bacterial skin microbiome in psoriatic arthritis, an unexplored link in pathogenesis: challenges and opportunities offered by recent technological advances. Rheumatology, 2014, 53, 777-784.	0.9	33
170	Enrichment of vitamin D response elements in RA-associated loci supports a role for vitamin D in the pathogenesis of RA. Genes and Immunity, 2013, 14, 325-329.	2.2	18
171	Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, 1375-1381.	0.5	94
172	Exploring ankylosing spondylitis-associated ERAP1, IL23R and IL12B gene polymorphisms in subphenotypes of psoriatic arthritis. Rheumatology, 2013, 52, 261-266.	0.9	36
173	An investigation of rheumatoid arthritis loci in patients with early-onset psoriasis validates association of the <i>REL</i> gene. British Journal of Dermatology, 2013, 168, 864-866.	1.4	11
174	Human SNP Links Differential Outcomes in Inflammatory and Infectious Disease to a FOXO3-Regulated Pathway. Cell, 2013, 155, 57-69.	13.5	200
175	Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients. Pharmacogenomics Journal, 2013, 13, 227-234.	0.9	91
176	MTHFR gene polymorphisms and outcome of methotrexate treatment in patients with rheumatoid arthritis: analysis of key polymorphisms and meta-analysis of C677T and A1298C polymorphisms. Pharmacogenomics Journal, 2013, 13, 137-147.	0.9	67
177	Rare, Low-Frequency, and Common Variants in the Protein-Coding Sequence of Biological Candidate Genes from GWASs Contribute to Risk of Rheumatoid Arthritis. American Journal of Human Genetics, 2013, 92, 15-27.	2.6	83
178	Investigation of Rheumatoid Arthritis Genetic Susceptibility Markers in the Early Rheumatoid Arthritis Study Further Replicates the <i>TRAF1</i> Association with Radiological Damage. Journal of Rheumatology, 2013, 40, 144-156.	1.0	22
179	Predicting the Risk of Rheumatoid Arthritis and Its Age of Onset through Modelling Genetic Risk Variants with Smoking. PLoS Genetics, 2013, 9, e1003808.	1.5	55
180	Brief Report: Identification of <i>BACH2</i> and <i>RAD51B</i> as Rheumatoid Arthritis Susceptibility Loci in a Metaâ€Analysis of Genomeâ€Wide Data. Arthritis and Rheumatism, 2013, 65, 3058-3062.	6.7	43

#	Article	IF	CITATIONS
181	Variants in <i>RUNX3</i> Contribute to Susceptibility to Psoriatic Arthritis, Exhibiting Further Common Ground With Ankylosing Spondylitis. Arthritis and Rheumatism, 2013, 65, 1224-1231.	6.7	63
182	Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis. PLoS Genetics, 2013, 9, e1003394.	1.5	146
183	The potential use of expression profiling: implications for predicting treatment response in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, 1118-1124.	0.5	38
184	Crowdsourcing genetic prediction of clinical utility in the Rheumatoid Arthritis Responder Challenge. Nature Genetics, 2013, 45, 468-469.	9.4	24
185	Investigation of C reactive protein gene polymorphisms as predictors of cardiovascular mortality in inflammatory polyarthritis: results from the Norfolk Arthritis Register: TableÂ1. Annals of the Rheumatic Diseases, 2013, 72, 1429-1430.	0.5	3
186	OP0213â€Identification of common susceptibility loci for inflammatory arthritis. Annals of the Rheumatic Diseases, 2013, 71, 128.1-128.	0.5	0
187	AB0180â€Relationship between area level socio-economic deprivation and autoantibody status in rheumatoid arthritis patients: Multicentre cross-sectional study. Annals of the Rheumatic Diseases, 2013, 71, 647.17-647.	0.5	Ο
188	SAT0007â€Fine-mapping of the 5Q31 psoriatic arthritis susceptibility LOCI in a british population. Annals of the Rheumatic Diseases, 2013, 71, 473.1-473.	0.5	0
189	THU0002â€Fine mapping and expression studies of the 12Q13-14 locus associated with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 71, 154.2-154.	0.5	0
190	SAT0014â€Correlation of CRP haplotypes with response to anti-TNF therapy in UK patients – results from the BRAGGSS cohort. Annals of the Rheumatic Diseases, 2013, 71, 475.2-475.	0.5	0
191	OP0210â€Enrichment of vitamin D response elements in RA associated loci, suggests a role for vitamin D in the pathogenesis of RA. Annals of the Rheumatic Diseases, 2013, 71, 126.3-127.	0.5	Ο
192	OP0214â€Investigation of rheumatoid arthritis genetic susceptibility markers in the early rheumatoid arthritis study (ERAS) provides further replication of the TRAF1/C5 association with radiological damage. Annals of the Rheumatic Diseases, 2013, 71, 128.2-128.	0.5	0
193	SAT0012â€Estimating heritability of response to treatment with anti-TNF biologic agents using linear mixed models. Annals of the Rheumatic Diseases, 2013, 71, 474.3-475.	0.5	1
194	THU0174â€Impact of IL-6R and IL-6ST Polymorphisms on Response to Anti-TNF Therapy in UK Patients – Results from the Braggss Cohort. Annals of the Rheumatic Diseases, 2013, 72, A222.1-A222.	0.5	0
195	THU0003â€Fine-mapping of autoimmune susceptibility LOCI using immunochip identifies novel susceptibility LOCI for psoriatic arthritis. Annals of the Rheumatic Diseases, 2013, 71, 154.3-155.	0.5	Ο
196	AB0436â€Patient acceptable symptom state in rheumatoid arthritis patients starting methotrexate correlates with age and patient reported outcomes. Annals of the Rheumatic Diseases, 2013, 71, 662.9-662.	0.5	0
197	A7.15â€Lack of Association of Variants Previously Associated with Anti-TNF Medication Response in Rheumatoid Arthritis Patients: Results from a Homogeneous Greek Population. Annals of the Rheumatic Diseases, 2013, 72, A53.1-A53.	0.5	0
198	THU0010â€A Weighted Genetic Risk Score Using 46 Loci to Predict Rheumatoid Arthritis Risk. Annals of the Rheumatic Diseases, 2013, 72, A167.3-A168.	0.5	3

#	Article	IF	CITATIONS
199	AB0289â€Can cd11c expression successfully predict response to etanercept in rheumatoid arthritis patients?. Annals of the Rheumatic Diseases, 2013, 72, A875.1-A875.	0.5	1
200	Lack of Association of Variants Previously Associated with Anti-TNF Medication Response in Rheumatoid Arthritis Patients: Results from a Homogeneous Greek Population. PLoS ONE, 2013, 8, e74375.	1.1	22
201	OP0050â€Fine Mapping and Expression of a Locus Overlapping 3 Types of Inflammatory Arthritis. Annals of the Rheumatic Diseases, 2013, 72, A66.3-A67.	0.5	1
202	Genetic markers of rheumatoid arthritis susceptibility in anti-citrullinated peptide antibody negative patients. Annals of the Rheumatic Diseases, 2012, 71, 1984-1990.	0.5	93
203	Informed Conditioning on Clinical Covariates Increases Power in Case-Control Association Studies. PLoS Genetics, 2012, 8, e1003032.	1.5	78
204	Heterogeneity of Anticitrullinated Peptide Antibodies and Response to Anti-Tumor Necrosis Factor Agents in Rheumatoid Arthritis. Journal of Rheumatology, 2012, 39, 929-932.	1.0	20
205	Idiopathic Orbital Inflammation Successfully Treated Using Rituximab in a Patient with Rheumatoid Arthritis: Figure 1 Journal of Rheumatology, 2012, 39, 1485-1486.	1.0	16
206	Investigation of rheumatoid arthritis susceptibility loci in juvenile idiopathic arthritis confirms high degree of overlap. Annals of the Rheumatic Diseases, 2012, 71, 1117-1121.	0.5	40
207	Comprehensive assessment of rheumatoid arthritis susceptibility loci in a large psoriatic arthritis cohort. Annals of the Rheumatic Diseases, 2012, 71, 1350-1354.	0.5	39
208	Rheumatoid Arthritis-associated Polymorphisms at 6q23 Are Associated with Radiological Damage in Autoantibody-positive RA. Journal of Rheumatology, 2012, 39, 1781-1785.	1.0	7
209	A genetic marker at the OLIG3/TNFAIP3 locus associates with methotrexate continuation in early inflammatory polyarthritis: results from the Norfolk Arthritis Register. Pharmacogenomics Journal, 2012, 12, 128-133.	0.9	14
210	Expression of the autoimmunity associated TNFAIP3 is increased in rheumatoid arthritis but does not differ according to genotype at 6q23. Rheumatology, 2012, 51, 1514-1515.	0.9	12
211	Relationship between area-level socio-economic deprivation and autoantibody status in patients with rheumatoid arthritis: multicentre cross-sectional study. Annals of the Rheumatic Diseases, 2012, 71, 1640-1645.	0.5	20
212	Idiopathic Orbital Inflammation Successfully Treated Using Rituximab in a Patient with Rheumatoid Arthritis. Journal of Rheumatology, 2012, 39, 1907-1907.	1.0	1
213	High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nature Genetics, 2012, 44, 1336-1340.	9.4	558
214	Investigation ofIL1,VEGF,PPARGandMEFVgenes in psoriatic arthritis susceptibility: Table 1. Annals of the Rheumatic Diseases, 2012, 71, 313-314.	0.5	15
215	Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Arthritis Research and Therapy, 2012. 14. R214.	1.6	18
216	Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nature Genetics, 2012, 44, 1341-1348.	9.4	848

#	Article	IF	CITATIONS
217	Genetics and the impact on treatment protocols in patients with rheumatoid arthritis. Expert Review of Clinical Immunology, 2012, 8, 509-511.	1.3	4
218	Investigation of Caucasian rheumatoid arthritis susceptibility loci in African patients with the same disease. Arthritis Research and Therapy, 2012, 14, R239.	1.6	17
219	Long-term stability of anti-cyclic citrullinated peptide antibody status in patients with early inflammatory polyarthritis. Arthritis Research and Therapy, 2012, 14, R109.	1.6	18
220	What Have Genome-Wide Studies Told Us About Psoriatic Arthritis?. Current Rheumatology Reports, 2012, 14, 364-368.	2.1	19
221	Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy. British Journal of Dermatology, 2012, 166, 474-482.	1.4	59
222	Confirmation of association ofFCGR3Bbut notFCGR3Acopy number with susceptibility to autoantibody positive rheumatoid arthritis. Human Mutation, 2012, 33, 741-749.	1.1	36
223	Replication of association of the <i>PTPRC</i> gene with response to anti–tumor necrosis factor therapy in a large UK cohort. Arthritis and Rheumatism, 2012, 64, 665-670.	6.7	65
224	Genetic and genomic predictors of anti-TNF response. Pharmacogenomics, 2011, 12, 1571-1585.	0.6	57
225	The role of rheumatoid arthritis genetic susceptibility markers in the prediction of erosive disease in patients with early inflammatory polyarthritis: results from the Norfolk Arthritis Register. Rheumatology, 2011, 50, 78-84.	0.9	32
226	Subtype specific genetic associations for juvenile idiopathic arthritis: ERAP1 with the enthesitis related arthritis subtype and IL23R with juvenile psoriatic arthritis. Arthritis Research and Therapy, 2011, 13, R12.	1.6	60
227	A systematic investigation of confirmed autoimmune loci in early-onset psoriasis reveals an association with IL2/IL21. British Journal of Dermatology, 2011, 164, no-no.	1.4	28
228	HLA-DPB1-COL11A2 and three additional xMHC loci are independently associated with RA in a UK cohort. Genes and Immunity, 2011, 12, 169-175.	2.2	15
229	Genomeâ€wide association study of genetic predictors of anti–tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis and Rheumatism, 2011, 63, 645-653.	6.7	143
230	Examining the overlap between genome-wide rare variant association signals and linkage peaks in rheumatoid arthritis. Arthritis and Rheumatism, 2011, 63, 1522-1526.	6.7	7
231	Evidence to support <i>IL-13</i> as a risk locus for psoriatic arthritis but not psoriasis vulgaris. Annals of the Rheumatic Diseases, 2011, 70, 1016-1019.	0.5	68
232	Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis. Annals of the Rheumatic Diseases, 2011, 70, 1641-1644.	0.5	103
233	Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients. Annals of the Rheumatic Diseases, 2011, 70, 98-103.	0.5	55
234	Study of the common genetic background for rheumatoid arthritis and systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2011, 70, 463-468.	0.5	130

#	Article	IF	CITATIONS
235	Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies. Annals of the Rheumatic Diseases, 2011, 70, 1713-1718.	0.5	36
236	ASSIMILATOR: a new tool to inform selection of associated genetic variants for functional studies. Bioinformatics, 2011, 27, 144-146.	1.8	8
237	Polymorphisms spanning the TNFR2 and TACE genes do not contribute towards variable anti-TNF treatment response. Pharmacogenetics and Genomics, 2010, 20, 338-341.	0.7	12
238	Genetic susceptibility factors for psoriatic arthritis. Current Opinion in Rheumatology, 2010, 22, 152-156.	2.0	21
239	Confirmation of association of the REL locus with rheumatoid arthritis susceptibility in the UK population. Annals of the Rheumatic Diseases, 2010, 69, 1572-1573.	0.5	32
240	Rare variation at the TNFAIP3 locus and susceptibility to rheumatoid arthritis. Human Genetics, 2010, 128, 627-633.	1.8	29
241	Benefit of early treatment in inflammatory polyarthritis patients with anti–cyclic citrullinated peptide antibodies versus those without antibodies. Arthritis Care and Research, 2010, 62, 664-675.	1.5	38
242	Association of a rheumatoid arthritis susceptibility variant at the CCL21 locus with premature mortality in inflammatory polyarthritis patients. Arthritis Care and Research, 2010, 62, 676-682.	1.5	13
243	Rheumatoid arthritis risk allele <i>PTPRC</i> is also associated with response to anti–tumor necrosis factor α therapy. Arthritis and Rheumatism, 2010, 62, 1849-1861.	6.7	95
244	Testing pharmacogenetic indices to predict efficacy and toxicity of methotrexate monotherapy in a rheumatoid arthritis patient cohort. Arthritis and Rheumatism, 2010, 62, 3827-3829.	6.7	9
245	Psoriatic arthritis – what the dermatologist needs to know. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 1270-1277.	1.3	18
246	Association of the AFF3 gene and IL2/IL21 gene region with juvenile idiopathic arthritis. Genes and Immunity, 2010, 11, 194-198.	2.2	54
247	Association of the CCR5 gene with juvenile idiopathic arthritis. Genes and Immunity, 2010, 11, 584-589.	2.2	24
248	Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature, 2010, 464, 713-720.	13.7	737
249	Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nature Genetics, 2010, 42, 436-440.	9.4	581
250	Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nature Genetics, 2010, 42, 508-514.	9.4	1,132
251	Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nature Genetics, 2010, 42, 996-999.	9.4	334
252	A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nature Genetics, 2010, 42, 985-990.	9.4	918

#	Article	IF	CITATIONS
253	Genetic Variants in Toll-Like Receptors Are Not Associated with Rheumatoid Arthritis Susceptibility or Anti-Tumour Necrosis Factor Treatment Outcome. PLoS ONE, 2010, 5, e14326.	1.1	24
254	Genetics [315-318]: 315. Investigation of Association of the Erap1 Gene with Psoriatic Arthritis. Rheumatology, 2010, 49, i152-i154.	0.9	0
255	Dissection of the FCGR3A association with RA: increased association in men and with autoantibody positive disease. Annals of the Rheumatic Diseases, 2010, 69, 1054-1057.	0.5	55
256	Combined effects of three independent SNPs greatly increase the risk estimate for RA at 6q23. Human Molecular Genetics, 2010, 19, 4544-4544.	1.4	0
257	PADI4 genotype is not associated with rheumatoid arthritis in a large UK Caucasian population. Annals of the Rheumatic Diseases, 2010, 69, 666-670.	0.5	73
258	Biomarkers of outcome in rheumatoid arthritis. Rheumatology Reports, 2010, 2, 3.	0.1	6
259	No evidence for association of the KLF12 gene with rheumatoid arthritis in a large UK cohort. Annals of the Rheumatic Diseases, 2010, 69, 1407-1408.	0.5	9
260	Overlap of disease susceptibility loci for rheumatoid arthritis and juvenile idiopathic arthritis. Annals of the Rheumatic Diseases, 2010, 69, 1049-1053.	0.5	61
261	Rheumatoid Arthritis: Treatment [151-201]: 151. Should we be Looking More Carefully for Methotrexate Induced Liver Disease?. Rheumatology, 2010, 49, i89-i111.	0.9	1
262	Identification of AF4/FMR2 family, member 3 (AFF3) as a novel rheumatoid arthritis susceptibility locus and confirmation of two further pan-autoimmune susceptibility genes. Human Molecular Genetics, 2010, 19, 4543-4543.	1.4	0
263	Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NFÂB signalling pathways. Annals of the Rheumatic Diseases, 2010, 69, 1315-1320.	0.5	74
264	Investigation of type 1 diabetes and coeliac disease susceptibility loci for association with juvenile idiopathic arthritis. Annals of the Rheumatic Diseases, 2010, 69, 2169-2172.	0.5	34
265	Concurrent Oral 6 - Spondylarthropathies [OP40-OP47]: OP40. Association of IL23R and IL12B Polymorphisms with Psoriatic Arthritis. Rheumatology, 2010, 49, i17-i20.	0.9	0
266	Genotype at the sIL-6R A358C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis. Rheumatology, 2010, 49, 43-47.	0.9	9
267	Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment. Annals of the Rheumatic Diseases, 2010, 69, 1029-1035.	0.5	89
268	Variants in linkage disequilibrium with the late cornified envelope gene cluster deletion are associated with susceptibility to psoriatic arthritis. Annals of the Rheumatic Diseases, 2010, 69, 2199-2203.	0.5	36
269	Association of CD40 with rheumatoid arthritis confirmed in a large UK case-control study. Annals of the Rheumatic Diseases, 2010, 69, 813-816.	0.5	62
270	Evaluation of the rheumatoid arthritis susceptibility loci HLA-DRB1, PTPN22, OLIG3/TNFAIP3, STAT4 and TRAF1/C5 in an inception cohort. Arthritis Research and Therapy, 2010, 12, R57.	1.6	37

#	Article	IF	CITATIONS
271	Overlapping genetic susceptibility variants between three autoimmune disorders: rheumatoid arthritis, type 1 diabetes and coeliac disease. Arthritis Research and Therapy, 2010, 12, R175.	1.6	92
272	Update on the genetic risk factors for rheumatoid arthritis. Expert Review of Clinical Immunology, 2010, 6, 61-75.	1.3	34
273	Genetic predictors of response to anti-tumor necrosis factor drugs in rheumatoid arthritis. Rheumatology Reports, 2009, 1, 1.	0.1	1
274	Identification of AF4/FMR2 family, member 3 (AFF3) as a novel rheumatoid arthritis susceptibility locus and confirmation of two further pan-autoimmune susceptibility genes. Human Molecular Genetics, 2009, 18, 2518-2522.	1.4	78
275	Investigation of association of genes NAT9, SLC9A3R1 and RAPTOR on chromosome 17q25 with psoriatic arthritis: Table 1. Annals of the Rheumatic Diseases, 2009, 68, 292-293.	0.5	6
276	Combined effects of three independent SNPs greatly increase the risk estimate for RA at 6q23. Human Molecular Genetics, 2009, 18, 2693-2699.	1.4	93
277	Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or <i>PTPN22</i> susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2009, 68, 69-74.	0.5	240
278	Investigating the viability of genetic screening/testing for RA susceptibility using combinations of five confirmed risk loci. Rheumatology, 2009, 48, 1369-1374.	0.9	20
279	Identification of a novel susceptibility locus for juvenile idiopathic arthritis by genome-wide association analysis. Arthritis and Rheumatism, 2009, 60, 258-263.	6.7	72
280	Association of the IL2RA/CD25 gene with juvenile idiopathic arthritis. Arthritis and Rheumatism, 2009, 60, 251-257.	6.7	93
281	Genetic susceptibility to rheumatoid arthritis: An emerging picture. Arthritis and Rheumatism, 2009, 61, 1441-1446.	6.7	79
282	Reevaluation of the interaction between HLA–DRB1 shared epitope alleles, PTPN22, and smoking in determining susceptibility to autoantibodyâ€positive and autoantibodyâ€negative rheumatoid arthritis in a large UK Caucasian population. Arthritis and Rheumatism, 2009, 60, 2565-2576.	6.7	86
283	Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nature Genetics, 2009, 41, 1313-1318.	9.4	306
284	A re-evaluation of three putative functional single nucleotide polymorphisms in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2009, 68, 1373-1375.	0.5	13
285	Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients. Pharmacogenetics and Genomics, 2009, 19, 319-323.	0.7	35
286	Association of the HLA–DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. Arthritis and Rheumatism, 2008, 58, 359-369.	6.7	161
287	Investigation of association of the IL12B and IL23R genes with psoriatic arthritis. Arthritis and Rheumatism, 2008, 58, 3705-3709.	6.7	122
288	Regulation of a novel αNâ€catenin splice variant in schizophrenic smokers. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 759-768.	1.1	25

#	Article	IF	CITATIONS
289	Rheumatoid arthritis susceptibility loci at chromosomes 10p15, 12q13 and 22q13. Nature Genetics, 2008, 40, 1156-1159.	9.4	143
290	Association of the FCRL3 gene with rheumatoid arthritis: a further example of population specificity?. Arthritis Research and Therapy, 2008, 10, 405.	1.6	0
291	Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Human Molecular Genetics, 2008, 17, 3532-3538.	1.4	111
292	The PTPN22*C1858T functional polymorphism is associated with susceptibility to inflammatory polyarthritis but neither this nor other variants spanning the gene is associated with disease outcome. Annals of the Rheumatic Diseases, 2008, 67, 251-255.	0.5	24
293	Re-evaluation of putative rheumatoid arthritis susceptibility genes in the post-genome wide association study era and hypothesis of a key pathway underlying susceptibility. Human Molecular Genetics, 2008, 17, 2274-2279.	1.4	131
294	A Genome-Wide Association Study of Psoriasis and Psoriatic Arthritis Identifies New Disease Loci. PLoS Genetics, 2008, 4, e1000041.	1.5	572
295	Investigation of association between the TRAF family genes and RA susceptibility. Annals of the Rheumatic Diseases, 2007, 66, 1322-1326.	0.5	41
296	Increasing age at symptom onset is associated with worse radiological damage at presentation in patients with early inflammatory polyarthritis. Annals of the Rheumatic Diseases, 2007, 66, 389-393.	0.5	36
297	Recent advances in the genetics of RA susceptibility. Rheumatology, 2007, 47, 399-402.	0.9	138
298	HLA-Cw6 and HLA-DRB1*07 together are associated with less severe joint disease in psoriatic arthritis. Annals of the Rheumatic Diseases, 2007, 66, 807-811.	0.5	64
299	Investigation of genetic variation across the protein tyrosine phosphatase gene in patients with rheumatoid arthritis in the UK. Annals of the Rheumatic Diseases, 2007, 66, 683-686.	0.5	30
300	Investigating the role of the HLA-Cw*06 and HLA-DRB1 genes in susceptibility to psoriatic arthritis: comparison with psoriasis and undifferentiated inflammatory arthritis. Annals of the Rheumatic Diseases, 2007, 67, 677-682.	0.5	92
301	Replication of Genome-Wide Association Signals in UK Samples Reveals Risk Loci for Type 2 Diabetes. Science, 2007, 316, 1336-1341.	6.0	2,040
302	The performance of anti–cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: Results from the Norfolk Arthritis Register. Arthritis and Rheumatism, 2007, 56, 2929-2935.	6.7	84
303	Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nature Genetics, 2007, 39, 1329-1337.	9.4	1,298
304	Rheumatoid arthritis association at 6q23. Nature Genetics, 2007, 39, 1431-1433.	9.4	361
305	Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature, 2007, 447, 661-678.	13.7	8,895
306	Fine mapping of genes within the IDDM8 region in rheumatoid arthritis. Arthritis Research and Therapy, 2006, 8, R145.	1.6	7

#	Article	IF	CITATIONS
307	Association of the FCRL3 gene with rheumatoid arthritis: a further example of population specificity?. Arthritis Research and Therapy, 2006, 8, R117.	1.6	36
308	Investigation of theMHC2TA gene, associated with rheumatoid arthritis in a Swedish population, in a UK rheumatoid arthritis cohort. Arthritis and Rheumatism, 2006, 54, 3417-3422.	6.7	21
309	Investigation of association of the DLG5 gene with psoriatic arthritis. Annals of the Rheumatic Diseases, 2006, 66, 273-274.	0.5	2
310	The epidemiology of rheumatoid arthritis and the use of linkage and association studies to identify disease genes. , 2006, , 9-28.		2
311	Investigation of theSLC22A4 gene (associated with rheumatoid arthritis in a Japanese population) in a United Kingdom population of rheumatoid arthritis patients. Arthritis and Rheumatism, 2005, 52, 752-758.	6.7	33
312	Association between thePTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: Further support thatPTPN22 is an autoimmunity gene. Arthritis and Rheumatism, 2005, 52, 1694-1699.	6.7	266
313	TNFR2 is not associated with rheumatoid arthritis susceptibility in a Caucasian population. Arthritis and Rheumatism, 2005, 52, 2579-2581.	6.7	7
314	Evidence for common genetic control in pathways of inflammation for Crohn's disease and psoriatic arthritis. Arthritis and Rheumatism, 2005, 52, 3596-3602.	6.7	65
315	Characterisation of the genomic architecture of human chromosome 17q and evaluation of different methods for haplotype block definition. BMC Genetics, 2005, 6, 21.	2.7	9
316	The type 1 diabetes susceptibility gene SUMO4 at IDDM5 is not associated with susceptibility to rheumatoid arthritis or juvenile idiopathic arthritis. Rheumatology, 2005, 44, 1390-1393.	0.9	16
317	Investigation of polymorphisms in the PADI4 gene in determining severity of inflammatory polyarthritis. Annals of the Rheumatic Diseases, 2005, 64, 1311-1315.	0.5	32
318	Polymorphisms in the tumour necrosis factor gene are not associated with severity of inflammatory polyarthritis. Annals of the Rheumatic Diseases, 2004, 63, 280-284.	0.5	30
319	Association of protein kinase C alpha (PRKCA) gene with multiple sclerosis in a UK population. Brain, 2004, 127, 1717-1722.	3.7	36
320	Genetic epidemiology of psoriatic arthritis. Modern Rheumatology, 2004, 14, 91-100.	0.9	6
321	Investigation of susceptibility loci identified in the UK rheumatoid arthritis whole-genome scan in a further series of 217 UK affected sibling pairs. Arthritis and Rheumatism, 2004, 50, 729-735.	6.7	39
322	Haplotype analysis in simplex families and novel analytic approaches in a case-control cohort reveal no evidence of association of the CTLA-4 gene with rheumatoid arthritis. Arthritis and Rheumatism, 2004, 50, 748-752.	6.7	50
323	A functional haplotype of thePADI4 gene associated with rheumatoid arthritis in a Japanese population is not associated in a United Kingdom population. Arthritis and Rheumatism, 2004, 50, 1117-1121.	6.7	186
324	Evidence for a novel rheumatoid arthritis susceptibility locus on chromosome 6p. Arthritis and Rheumatism, 2004, 50, 3823-3830.	6.7	18

#	Article	IF	CITATIONS
325	Whole-Genome Scan, in a Complex Disease, Using 11,245 Single-Nucleotide Polymorphisms: Comparison with Microsatellites. American Journal of Human Genetics, 2004, 75, 54-64.	2.6	209
326	Dissection of Complex Genetic Disease. Clinical Orthopaedics and Related Research, 2004, 419, 297-305.	0.7	5
327	Polymorphisms in the mannose binding lectin (MBL) gene are not associated with radiographic erosions in rheumatoid or inflammatory polyarthritis. Journal of Rheumatology, 2004, 31, 442-7.	1.0	18
328	Genetic epidemiology of psoriatic arthritis. Modern Rheumatology, 2004, 14, 91-100.	0.9	4
329	Genetic variation in CCR5 does not predict clinical outcome in inflammatory arthritis. Arthritis and Rheumatism, 2003, 48, 3615-3616.	6.7	19
330	Linkage analysis of cross-sectional and longitudinally derived phenotypic measures to identify loci influencing blood pressure. BMC Genetics, 2003, 4, S26.	2.7	2
331	Macrophage migration inhibitory factor (MIF) gene polymorphism is associated with susceptibility to but not severity of inflammatory polyarthritis. Genes and Immunity, 2003, 4, 487-491.	2.2	76
332	Approaches to Identifying Genetic Predictors of Clinical Outcome in Rheumatoid Arthritis. Molecular Diagnosis and Therapy, 2003, 3, 181-191.	3.3	5
333	Genetic approaches to the investigation of rheumatoid arthritis. Current Opinion in Rheumatology, 2002, 14, 260-269.	2.0	22
334	Commentary on "Genetic linkage and transmission disequilibrium of marker haplotypes at chromosome 1q41 in human systemic lupus erythematosus", by RR Graham et al. Arthritis Research, 2002, 4, 84.	2.0	0
335	Genetic epidemiology. Psoriatic arthritis. Arthritis Research, 2002, 4, 247.	2.0	16
336	Whole-genome linkage analysis of rheumatoid arthritis susceptibility loci in 252 affected sibling pairs in the United Kingdom. Arthritis and Rheumatism, 2002, 46, 632-639.	6.7	184
337	The Singleâ€Nucleotide Polymorphism Lottery: How Useful are a Few Common SNPs in Identifying Diseaseâ€Associated Alleles?. Genetic Epidemiology, 2001, 21, S384-9.	0.6	6
338	Association between rheumatoid arthritis and polymorphism of tumor necrosis factor receptor II, but not tumor necrosis factor receptor I, in Caucasians. Arthritis and Rheumatism, 2001, 44, 61-65.	6.7	118
339	High resolution linkage and association mapping identifies a novel rheumatoid arthritis susceptibility locus homologous to one linked to two rat models of inflammatory arthritis. Human Molecular Genetics, 2001, 10, 1901-1906.	1.4	52
340	Syntenic mapping of human disease genes using animal models of autoimmunity. GeneScreen, 2000, 1, 3-7.	0.7	0
341	A single nucleotide polymorphism in exon 1 of cytotoxic T-lymphocyte-associated-4 (CTLA-4) is not associated with rheumatoid arthritis. Rheumatology, 2000, 39, 63-66.	0.9	43
342	Mycobacterium marinum infection causing septic arthritis and osteomyelitis. Rheumatology, 1997, 36, 1207-1209.	0.9	55